Inotuzumab Ozogamicin Shows Clear Benefit in Acute Lymphoblastic Leukemia

In patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the antibody-drug conjugate inotuzumab ozogamicin produced...

Health-Care Policy

How the Oncology Center of Excellence Plans to Foster Collaboration Among Researchers to Advance Cancer Treatment

On June 29, 2016, Robert M. Califf, MD, MACC, the Commissioner of the U.S. Food and Drug Administration (FDA), announced the selection...

Issues in Oncology

Have You Received Your Immune Checkpoint Inhibitor Yet?

“Have you received your immune checkpoint inhibitor yet?” I suspect St. Peter may have started asking this question routinely at the...


More Top Stories


James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma

Gynecologic Cancers

FDA Approves First HPV Test for Use With SurePath Preservative Fluid

On July 7, 2016, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for human papillomavirus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid.

The FDA approves HPV tests to be...


Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...


Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics

OmniSeq Receives New York CLEP Approval for 144-Gene Comprehensive Panel, Partners With Cure Forward

OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive panel, a 144-gene, pan-cancer, next-generation sequencing tumor-profiling diagnostic panel to guide oncology treatment...

ASTRO Members Elect Five New Officers to Board of Directors

Members of the American Society for Radiation Oncology ­(ASTRO) have elected five new officers to the Society’s Board of Directors, including President-Elect, Secretary/Treasurer-Elect, and Vice-Chairs of three of ASTRO’s five councils (Clinical Affairs and Quality, Education, and Government...

Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated

The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer.

HRT is used to treat...

Cost of Care
Issues in Oncology

Yousuf Zafar, MD, on the Financial Burden of Cancer Care

Issues in Oncology

New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade

American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1

Small Percentage Responsible for ...


Increased Uveal Melanoma Risk Linked to Pigmentation Genes That Dictate Eye Color

New research links specific inherited genetic alterations to an increased risk for uveal melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. These findings were published by Ferguson et al in Scientific Reports.

Previous clinical data suggests uveal melanoma...